| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CH5424802 | GDSC1000 | pan-cancer | AAC | 0.48 | 9e-54 |
| mRNA | MPS-1-IN-1 | GDSC1000 | pan-cancer | AAC | 0.3 | 4e-23 |
| mRNA | XMD14-99 | GDSC1000 | pan-cancer | AAC | 0.29 | 1e-20 |
| mRNA | TAE684 | GDSC1000 | pan-cancer | AAC | 0.4 | 2e-16 |
| mRNA | TAE684 | CTRPv2 | pan-cancer | AAC | 0.26 | 1e-14 |
| mRNA | XMD15-27 | GDSC1000 | pan-cancer | AAC | 0.25 | 3e-14 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | 0.36 | 2e-13 |
| mRNA | HG-5-88-01 | GDSC1000 | pan-cancer | AAC | 0.29 | 2e-11 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.2 | 2e-09 |
| mRNA | TAE684 | CCLE | pan-cancer | AAC | 0.24 | 2e-08 |